2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163736
    mPGES-1/5-LOX-IN-1 98%
    mPGES-1/5-LOX-IN-1 (compound 3j) is a potent and orally active mPGES-1 and 5-LOX dual inhibitor with IC50 values of 0.92, 1.89 µM, respectively. mPGES-1/5-LOX-IN-1 shows anti-inflammatory impact.
    mPGES-1/5-LOX-IN-1
  • HY-163744
    NLRP3-IN-42 3040024-62-9 98%
    NLRP3-IN-42 (compound H28) is a potent NLRP3 inhibitor with an KD value of 1.15 µM. NLRP3-IN-42 decreases the LPS (HY-D1056) induced protein expression of cleaved-caspase-1 (p20). NLRP3-IN-42 selectively inhibits IL-1β release.
    NLRP3-IN-42
  • HY-163748
    GSK-3β inhibitor 17 2521624-67-7 98%
    GSK-3β inhibitor 17 (compound 5 n) is a potent GSK-3β inhibitor. GSK-3β inhibitor 17 decreases cisplatin (HY-17394) induced p-p65, KIM-1 protein and mRNA expression. GSK-3β inhibitor 17 decreases cisplatin induced TNF-α, IL-1β, IL-6 and MCP-1 mRNA expression. GSK-3β inhibitor 17 shows anti-inflammation effect and has the potential for the research of acute kidney injury.
    GSK-3β inhibitor 17
  • HY-163749
    STING-IN-8 98%
    STING-IN-8 (Compound 15b) emerges as a potent stimulator of interferon gene (STING) inhibitor with an IC50 value of 0.121 μM in human and an IC50 value of 0.033 μM in mouse. STING-IN-8 inhibits MSA-2 (HY-136927) or 2’, 3’ -cGAMP (HY-100564)-stimulated STING signaling and suppresses immune-inflammatory cytokine levels in both human and murine cells. STING-IN-8 is promising for research in the field of STING-associated inflammatory and autoimmune diseases.
    STING-IN-8
  • HY-163750
    KMU-11342 98%
    KMU-11342 is a potent inhibitor of multi-protein kinase. KMU-11342 plays an important inhibitor of rheumatoid arthritis (RA) research.
    KMU-11342
  • HY-163755
    GPER activator 1 2629960-35-4 98%
    GPER activator 1 (compound 6-26) is a GPER-selective compound without cytotoxicity. GPER activator 1 exhibits dual inhibition of TNFα- and IL-6-induced inflammation.
    GPER activator 1
  • HY-163756
    NLRP3-IN-43 2769903-01-5 98%
    NLRP3-IN-43 (compound II-8) is a poteny inhibitor of NLRP3 inflammasome activation that binds to the LRR domain, and disrupts NLRP3-NEK7 interaction.
    NLRP3-IN-43
  • HY-163775
    Anti-inflammatory agent 88 98%
    Anti-inflammatory agent 88 (compound 6) is a carbazole derivative with anti-inflammatory activity found in marine Streptomyces. It exerts its anti-inflammatory effect by inhibiting pro-inflammatory factors and enhancing the expression of anti-inflammatory factors in the Myd88/Nf-κB pathway. Anti-inflammatory agent 88 can be used for the development of anti-inflammatory drugs.
    Anti-inflammatory agent 88
  • HY-163777
    Talaroterphenyl A 98%
    Talaroterphenyl A (compound 1) is a p-terphenyl derivative present in the mangrove sediment-derived fungus Talaromyces sp. SCSIO 41412, which exhibits phosphodiesterase 4 (PDE4) inhibitory activity (IC50=1.2 μM). Talaroterphenyl A also exhibits anti-inflammatory and anti-fibrotic activities, significantly reducing the mRNA levels of pro-inflammatory cytokines IL-6, TNF-α, and IL-1β.
    Talaroterphenyl A
  • HY-163778
    ZM600 98%
    ZM600 is a potent and orally active antihepatic fibrosis agent. ZM600 decreases the LPS (HY-D1056) induced protein expression of collagen I, α-SM, p-p65. ZM600 has the potential for the research of liver fibrosis.
    ZM600
  • HY-163825
    RNB-61 98%
    RNB-61 is an oral active agonist of cannabinoid CB2 receptor (CB2R), with the Ki ranging from 0.13 nM to 1.81 nM. RNB-61 has nephroprotective and/or antifibrotic effects. RNB-61 has negligible penetration into the brain.
    RNB-61
  • HY-163842
    Cathepsin K inhibitor 7 98%
    Cathepsin K inhibitor 7 (compound 7) is a Cathepsin K inhibitor with the pKi of 7.3 aganist CatK. Cathepsin K inhibitor 7 can be used for study of osteoporosis.
    Cathepsin K inhibitor 7
  • HY-163844
    PD-1/PD-L1-IN-49 98%
    PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1, with the IC50 of 77 nM. PD-1/PD-L1-IN-49 activates Jurkat T cells, reflecting successful blockade of the PD-1/PD-L1 immune checkpoint.
    PD-1/PD-L1-IN-49
  • HY-163847
    Anti-osteoporosis agent-9 98%
    Anti-osteoporosis agent-9 (compound 5b) is a N-cyclopropyl-4-((4-((4-(trifluoromethyl)phenyl)sulfonyl)piperazin-1-yl)methyl)benzamide derivative that shows anti-osteoclast activity.
    Anti-osteoporosis agent-9
  • HY-163848
    Anti-inflammatory agent 90 3053522-48-5 98%
    Anti-inflammatory agent 90 (compound (R)-7) demonstrates decreasing of 32 % and 40 % for nitrite and IL-6, respectively in LPS-challenged RAW cells.
    Anti-inflammatory agent 90
  • HY-163849
    Mizoribine prodrug-1 2237237-22-6 98%
    Mizoribine prodrug-1 (compound 18) is a oral active ester-based mizoribine (HY-17470) prodrug. Mizoribine prodrug-1 displays a inhibition of IL-2 production.
    Mizoribine prodrug-1
  • HY-163850
    Mizoribine prodrug-2 trifluoroacetate 2237237-32-8 98%
    Mizoribine prodrug-2 trifluoroacetate (compound 20) is a oral active mizoribine (HY-17470) prodrug (amino acid conjugate). Mizoribine prodrug-2 displays a prolonged inhibition of IL-2 production.
    Mizoribine prodrug-2 trifluoroacetate
  • HY-163862
    PPARα agonist 3 98%
    PPARα agonist 3 (Compound A229) is a PPARα agonist (EC50: 590 nM). PPARα agonist 3 inhibits TBHP or 4-HNE (HY-113466)-induced production of ROS.
    PPARα agonist 3
  • HY-163888
    NO-IN-1 98%
    NO-IN-1 (Compound 7a) inhibits the production of NO (IC50 = 3.13 μΜ). NO-IN-1 has anti-inflammatory effects. NO-IN-1 downregulates the expression of COX-2 and iNOS by inhibiting the NF-κB signaling pathway.
    NO-IN-1
  • HY-163982
    FOXJ1 agonist 1 98%
    FOXJ1 agonist 1 (compound 16c) is an orally effective small molecule that can effectively enhance the expression of FOXJ1. Foxj1-IN-1 acts on the mammalian airway system composed of multiciliated cells (MCC) to prevent the development and onset of chronic obstructive pulmonary disease (COPD). Foxj1-IN-1 can induce the production of motile cilia in the respiratory system of zebrafish and mammals, and inhibit elastase-induced COPD mouse models. Foxj1-IN-1 has good liver microsomal stability, in vivo PK curve and AUC; it has no significant inhibition of CYP and hERG, and does not have significant cytotoxicity.
    FOXJ1 agonist 1
Cat. No. Product Name / Synonyms Application Reactivity